50 related articles for article (PubMed ID: 7564529)
1. P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases.
Damiani D; Michieli M; Michelutti A; Pea F; Baraldo M; Fanin R; Russo D; Furlanut M; Baccarani M
Leukemia; 1995 Oct; 9(10):1792-5. PubMed ID: 7564529
[No Abstract] [Full Text] [Related]
2. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
[TBL] [Abstract][Full Text] [Related]
3. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Maia RC; Carriço MK; Klumb CE; Noronha H; Coelho AM; Vasconcelos FC; Ruimanek VM
J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
[TBL] [Abstract][Full Text] [Related]
4. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia.
Damiani D; Michieli M; Michelutti A; Fanin R; Russo D; Baccarani M
Leuk Lymphoma; 1995 Apr; 17(3-4):289-94. PubMed ID: 8580798
[TBL] [Abstract][Full Text] [Related]
5. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia.
Michelutti A; Michieli M; Damiani D; Melli C; Geromin A; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(3):200-4. PubMed ID: 7926967
[TBL] [Abstract][Full Text] [Related]
7. Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype.
Krumpochova P; Kocurova A; Dolezel P; Mlejnek P
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1875-80. PubMed ID: 21641880
[TBL] [Abstract][Full Text] [Related]
8. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Bassan R; Lerede T; Borleri G; Chiodini B; Rossi A; Buelli M; Rambaldi A; Viero P; Barbui T
Haematologica; 2002 Mar; 87(3):257-63. PubMed ID: 11869937
[TBL] [Abstract][Full Text] [Related]
12. [Antisense oligonucleotides increase the apoptotic effect of idarubicin in K-562 cell line].
Vellón L; Cuello T; Gargallo P; Larripa I
Medicina (B Aires); 2000; 60(1):143-5. PubMed ID: 10835712
[TBL] [Abstract][Full Text] [Related]
13. Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines.
Duffy PM; Hayes MC; Cooper A; Smart CJ
Br J Cancer; 1996 Sep; 74(6):906-9. PubMed ID: 8826856
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
15. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
Zong Y; Zhou S; Sorrentino BP
Leukemia; 2005 Sep; 19(9):1590-6. PubMed ID: 16001089
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Giles FJ; Kantarjian HM; Cortes J; Thomas DA; Talpaz M; Manshouri T; Albitar M
Cancer; 1999 Sep; 86(5):805-13. PubMed ID: 10463979
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ
Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298
[TBL] [Abstract][Full Text] [Related]
19. Nicardipine as a chemosensitizing agent in two P-glycoprotein-positive leukemic patients.
Carulli G; Petrini M; Caracciolo F; Marini A; Grassi B
Haematologica; 1990; 75(3):300-1. PubMed ID: 1977669
[No Abstract] [Full Text] [Related]
20. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
